Internal Medicine, Hematology & Oncology · Beverly Hills, CA
NPI
1659412757
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
8900 Wilshire Blvd
Beverly Hills, CA, 90211
Phone (310) 432-8900
Groups this clinician bills Medicare through
Medicare paid, 2024
$745K
97,722 services
Medicare patients, 2024
475
Average age 74
Drug cost, 2024
$4.9M
1,009 prescriptions
Company payments, 2025
$7,468
From 55 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Afshin E Gabayan was code J1439 (injection, ferric carboxymaltose, 1 mg), 18,750 times for 15 patients. In total Afshin E Gabayan billed 97,722 services in 129 codes, and Medicare paid $745K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 18,750 | 15 | $0.88 | $16K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 13,770 | 14 | $0.28 | $3,794 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,700 | 13 | $15.47 | $26K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,380 | 16 | $0.07 | $101 |
| J0897 Injection, denosumab, 1 mg | Office | 1,380 | 13 | $18.61 | $26K |
| 80053 Clinical Chemistry | Office | 1,134 | 433 | $10.34 | $12K |
| 85025 Blood Count | Office | 1,047 | 340 | $7.60 | $7,961 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,018 | 17 | $0.09 | $89.23 |
| 36415 Venipuncture Blood Collection | Office | 711 | 289 | $8.63 | $6,136 |
| 83615 Clinical Chemistry | Office | 475 | 226 | $5.91 | $2,807 |
| 99215 Office E&M - Established | Office | 431 | 179 | $149.59 | $64K |
| 82977 Clinical Chemistry | Office | 339 | 165 | $7.06 | $2,393 |
| 99214 Office E&M - Established | Office | 311 | 196 | $102.94 | $32K |
| 82378 Clinical Chemistry | Office | 291 | 129 | $18.58 | $5,407 |
| 83540 Clinical Chemistry | Office | 288 | 146 | $6.34 | $1,826 |
By year: 2022 $523K for 78,400 services; 2023 $579K for 99,354 services; 2024 $745K for 97,722 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80053 Clinical Chemistry | 1,134 | 433 | $10.34 | $12K |
| 85025 Blood Count | 1,047 | 340 | $7.60 | $7,961 |
| 36415 Venipuncture Blood Collection | 711 | 289 | $8.63 | $6,136 |
| 83615 Clinical Chemistry | 475 | 226 | $5.91 | $2,807 |
| 82977 Clinical Chemistry | 339 | 165 | $7.06 | $2,393 |
| 82378 Clinical Chemistry | 291 | 129 | $18.58 | $5,407 |
| 83540 Clinical Chemistry | 288 | 146 | $6.34 | $1,826 |
| 82728 Clinical Chemistry | 285 | 145 | $13.36 | $3,808 |
| 84100 Clinical Chemistry | 228 | 124 | $4.65 | $1,060 |
| 84402 Clinical Chemistry | 228 | 102 | $24.87 | $5,671 |
Medicare prescription drug claims, 2024
In 2024, the drug Afshin E Gabayan prescribed most often to Medicare patients was Xtandi (Enzalutamide), with 74 prescriptions and refills. In total Afshin E Gabayan wrote 1,009 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | 74 | 74 | 11 | $1.0M |
| Jakafi Ruxolitinib Phosphate | 38 | 38 | Under 11 | $528K |
| Orgovyx Relugolix | 35 | 35 | Under 11 | $95K |
| Zoledronic Acid Generic | 28 | 47 | Under 11 | $816 |
| Yonsa Abiraterone Acet,submicronized | 25 | 25 | Under 11 | $242K |
| Dexamethasone Sodium Phosphate Generic | 24 | 24 | Under 11 | $40.08 |
| Eligard Leuprolide Acetate | 23 | 69 | Under 11 | $28K |
| Levofloxacin Generic | 20 | 20 | 17 | $86.77 |
| Ondansetron Hcl Generic | 19 | 19 | 11 | $231 |
| Stivarga Regorafenib | 18 | 18 | Under 11 | $305K |
| Diphenhydramine Hcl Generic | 18 | 18 | Under 11 | $19.88 |
| Hydroxyurea Generic | 18 | 38 | Under 11 | $769 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 18 | 18 | Under 11 | $39.9 |
| Anastrozole Generic | 17 | 25 | Under 11 | $226 |
| Erleada Apalutamide | 17 | 17 | Under 11 | $241K |
Brand drugs: 474 claims; generic drugs: 535 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Afshin E Gabayan $7,468 ($6,422 in general payments such as food, travel and fees and $1,046 for research) from 55 companies. The largest payer was Pfizer Inc. with $1,247.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 17 | $1,247 |
| Janssen Biotech, Inc. JNJ | 17 | $1,181 |
| AstraZeneca Pharmaceuticals LP AZN | 28 | $885 |
| Abbvie Inc. ABBV | 11 | $379 |
| Daiichi Sankyo Inc. 4568.T | 15 | $361 |
| BeOne Medicines USA, Inc. ONC | 5 | $262 |
| Stemline Therapeutics Inc. | 5 | $190 |
| Syndax Pharmaceuticals, Inc. SNDX | 3 | $189 |
| Telix Pharmaceuticals TLX | 3 | $183 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 6 | $150 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.